PMC:7299399 / 21953-23170
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T102 | 363-370 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T103 | 406-413 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T79 | 482-492 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T80 | 657-665 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T224 | 232-233 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T225 | 570-572 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
| T226 | 839-845 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T227 | 849-850 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T228 | 892-893 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T229 | 990-993 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T230 | 1031-1038 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T231 | 1059-1060 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T137 | 291-293 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
| T138 | 363-370 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T139 | 406-413 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T140 | 859-861 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
| T141 | 1067-1075 | Chemical | denotes | aluminum | http://purl.obolibrary.org/obo/CHEBI_28984 |
| T142 | 1076-1080 | Chemical | denotes | salt | http://purl.obolibrary.org/obo/CHEBI_24866|http://purl.obolibrary.org/obo/CHEBI_26710 |
| T144 | 1082-1086 | Chemical | denotes | alum | http://purl.obolibrary.org/obo/CHEBI_74768 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T95 | 302-1058 | Sentence | denotes | Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 328 | 108-120 | Species | denotes | participants | Tax:9606 |
| 336 | 851-861 | Gene | denotes | Phase I/II | |
| 337 | 657-667 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 339 | 1067-1080 | Chemical | denotes | aluminum salt | |
| 340 | 1082-1086 | Chemical | denotes | alum | |
| 341 | 482-501 | Disease | denotes | infectious diseases | MESH:D003141 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32519842-32259480-158492 | 570-572 | 32259480 | denotes | 27 |
| 32519842-32259480-158493 | 668-670 | 32259480 | denotes | 27 |